MoonLake Immunotherapeutics MLTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$259.47M-12.7% | -$230.32M-7.8% | -$213.7M-19.3% | -$179.12M-21.2% | -$147.83M-21.9% | ||
| $3.08M+17.9% | $2.62M+17.4% | $2.23M+21.5% | $1.84M+27.9% | $1.44M+3.6% | ||
| $23.96M+85.8% | $12.9M+14.7% | $11.24M+19.9% | $9.38M+18.8% | $7.9M+8.4% | ||
| $11.37M-44.7% | $20.56M— | —— | —— | —— | ||
| —— | —— | $13.66M+369% | $2.91M-54.6% | $6.42M+24.2% | ||
| —— | —— | —— | —— | $1.7M— | ||
| —— | —— | —— | $1.33M+13,350% | -$10K-104% | ||
| $9.81M+1,849% | -$561K-106% | $8.67M— | —— | —— | ||
| -$43K+25.9% | -$58K-152% | -$23K-229% | -$7K-133% | -$3K-400% | ||
| -$1.36M-11.0% | -$1.22M+12.5% | -$1.4M-22.0% | -$1.14M+10.1% | -$1.27M+10.6% | ||
| $2.77M+36.9% | $2.03M+25.5% | $1.61M-6.8% | $1.73M+16.0% | $1.49M-16.4% | ||
| -$224.15M-14.4% | -$196.01M-5.6% | -$185.69M-11.6% | -$166.42M-19.1% | -$139.78M-19.9% | ||
| —— | —— | —— | —— | $343K-34.0% | ||
| $235.89M-11.1% | $265.37M-24.9% | $353.15M-7.6% | $382.33M+8.9% | $351.11M+0.2% | ||
| $382.74M-18.3% | $468.4M— | —— | —— | —— | ||
| —— | —— | $85.57M— | —— | —— | ||
| —— | —— | —— | —— | $73.02M— | ||
| —— | —— | —— | —— | —— | ||
| $103.52M-29.1% | $146M+98.0% | $73.75M+0.4% | $73.46M0.0% | $73.46M+43.2% | ||
| —— | —— | —— | $1.4M— | —— | ||
| —— | —— | -$24.92M— | —— | —— | ||
| $6.88M+36.0% | $5.06M+76.2% | $2.87M+148% | $1.16M— | —— | ||
| —— | —— | $13.66M+369% | $2.91M-54.6% | $6.42M+24.2% | ||
| -$1.36M-11.0% | -$1.22M+12.5% | -$1.4M-22.0% | -$1.14M+10.1% | -$1.27M+10.6% | ||
| $30K— | $0-100% | $1K— | —— | —— | ||
| $2.77M+36.9% | $2.03M+25.5% | $1.61M-6.8% | $1.73M+16.0% | $1.49M-16.4% | ||
| $9.81M+1,849% | -$561K-106% | $8.67M— | —— | —— | ||
| —— | —— | —— | $1.33M+13,350% | -$10K-104% | ||
| -$43K+25.9% | -$58K-152% | -$23K-229% | -$7K-133% | -$3K-400% | ||
| $382.74M-18.3% | $468.4M— | —— | —— | —— | ||
| —— | —— | —— | $1.4M— | —— | ||
| -$1.36M-11.0% | -$1.22M+12.5% | -$1.4M-22.0% | -$1.14M+10.1% | -$1.27M+10.6% | ||
| $567K— | $0— | —— | —— | —— | ||
| -$224.15M-14.3% | -$196.04M-5.5% | -$185.9M-11.5% | -$166.76M-19.0% | -$140.12M-19.7% | ||
| -$224.15M-14.3% | -$196.04M-5.5% | -$185.9M-11.5% | -$166.76M-19.0% | -$140.12M-19.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MoonLake Immunotherapeutics generate?
- MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
- What is MoonLake Immunotherapeutics's free cash flow?
- After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
- Where does MoonLake Immunotherapeutics's cash flow data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.